Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) Shares Outstanding (Weighted Average) (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Shares Outstanding (Weighted Average) for 5 consecutive years, with $46.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 6.2% to $46.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.0 million through Dec 2025, up 6.2% year-over-year, with the annual reading at $46.0 million for FY2025, 6.2% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $46.0 million at Werewolf Therapeutics, up from $45.2 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $46.0 million in Q4 2025, with the low at $1.2 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $33.5 million, with a median of $35.4 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) surged 2128.89% in 2022, then grew 3.44% in 2025.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $18.5 million in 2021, then surged by 56.4% to $28.9 million in 2022, then grew by 23.5% to $35.6 million in 2023, then increased by 21.56% to $43.3 million in 2024, then rose by 6.2% to $46.0 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $46.0 million, $45.2 million, and $44.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.